BRIEF-Cytrx reports statistically significant updated results from pivotal phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcomas

* Cytrx-Reports statistically significant updated results

from pivotal phase 3 trial of aldoxorubicin in patients with

second-line soft tissue sarcomas

Read more